Key result
Metoprolol use in hypertensive pregnant women was associated with lower perinatal mortality (2.0% vs 8.0%) and fetal growth retardation (11.7% vs 16.3%) compared to hydralazine.
Why the study?
Does metoprolol reduce perinatal mortality and fetal growth retardation in hypertensive pregnant women compared to hydralazine?
Population
198 hypertensive gravidae (pregnant women)
Comparison
Metoprolol alone or in combination with… vs Hydralazine with a small dose of a thiazide added
Design
Cohort
Authors
Loading...
Metoprolol may be associated with better perinatal outcomes than hydralazine; leaves open need for randomized confirmation before practice change.
Cohort (n=198)
Does metoprolol reduce perinatal mortality and fetal growth retardation in hypertensive pregnant women compared to hydralazine?
Absolute Event Rate: 2% vs 8%
Metoprolol appears to be safe and associated with lower perinatal mortality and fetal growth retardation compared to hydralazine in the treatment of hypertension during pregnancy.
Bo Sandström (2010) conducted a cohort in Hypertension in pregnancy (n=198). Metoprolol (alone or in combination with hydralazine) vs. Hydralazine was evaluated on Perinatal mortality. Metoprolol use in hypertensive pregnant women was associated with lower perinatal mortality (2.0% vs 8.0%) and fetal growth retardation (11.7% vs 16.3%) compared to hydralazine.